SCHEMBL19459182

SCHEMBL19459182

CC(C)(C)OC(=O)Oc1ccc(C2(C)CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.48
▸ CTSD P07339 1/20 0.42
▸ CTSE P14091 1/20 0.42
▸ BACE1 P56817 1/20 0.42
▸ MMP13 P45452 2/20 0.42
▸ ADAM17 P78536 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GPR119 Q8TDV5 7/20 0.41
▸ MAPT P10636 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19459178 0.84 ESR2 (0.48) ALDH1A1TSHRALOX15ATMMEN1
SCHEMBL13608428 0.84 GPR119 (0.53) MMP13ALDH1A1TSHRALOX15ATM
SCHEMBL16764329 0.83 NR1H2 (0.49) CTSDCTSEBACE1ALDH1A1TSHR
SCHEMBL16764525 0.83 RORC (0.53) ALDH1A1TSHRALOX15ATMMEN1
SCHEMBL3246933 0.82 TSHR (0.57) TSHRALOX15ATMMEN1KMT2A
SCHEMBL19482467 0.82 ELANE (0.54) ELANEALDH1A1TSHRATMMEN1
SCHEMBL23411856 0.82 GPR119 (0.55) ALDH1A1TSHRALOX15ATMMEN1
SCHEMBL19459171 0.81 RORC (0.46) MMP13ADAM17TSHRALOX15ATM
SCHEMBL24350986 0.81 TSHR (0.42) CTSDCTSEBACE1ALDH1A1TSHR
SCHEMBL19486861 0.80 ELANE (0.51) ELANEMMP13ADAM17ATMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595265-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2026-04-07 — — US disclosed
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2024-05-16 — — US disclosed
EP-4285996-A2 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2023-12-06 — — EP disclosed
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP disclosed
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 — — EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 — — US disclosed
US-20220315585-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2022-10-06 — — US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 — — US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 — — US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 — — US disclosed
EP-3442977-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE Blueprint Medicines Corporation (US) 2019-02-20 — — EP disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 — — US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 ELANE 4614/4885CTSD 2766/4885CTSE 2144/4885
US-20240158398-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ELANE 4614/4885CTSD 2766/4885CTSE 2144/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ELANE 4614/4885CTSD 2766/4885CTSE 2144/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 ELANE 4614/4885CTSD 2766/4885CTSE 2144/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 ELANE 4493/4885CTSD 2926/4885CTSE 2312/4885
US-12595265-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVRL1, ACVR2A ELANE 4133/4885CTSD 1849/4885CTSE 1194/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ELANE 4614/4885CTSD 2766/4885CTSE 2144/4885
US-20220315585-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 ELANE 4614/4885CTSD 2766/4885CTSE 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback